Stock Market Impact: Insulet Corporation (NASDAQ:PODD) shares dropped approximately 6% in after‑hours trading on 27‑05‑2026 following the announcement of a voluntary medical device correction and recall.
Recall Details: The recall covers specific lots of Omnipod 5, Omnipod DASH and Omnipod Eros (Insulin Management System) pods due to a manufacturing defect—a small tear in the tubing above the skin—that may cause insulin under‑delivery. Approximately 7 million pods are affected, representing about 8.5% of the company’s projected 2025 global Omnipod pod production. Roughly 60% of the recalled pods have already been consumed or are expired.
Adverse Events: Insulet reported 24 serious adverse events worldwide linked to high blood glucose, including hospitalizations and diabetic ketoacidosis; no deaths were reported.
Regulatory Context: This recall is separate from a prior voluntary medical device correction issued on 12 March 2026 for certain Omnipod 5 pods in the United States. The U.S. Food and Drug Administration (FDA) and other relevant regulatory authorities have been notified.
Company Response: Insulet identified the root cause, implemented corrective actions, and strengthened in‑process monitoring and quality controls to detect cannula tears. The company is communicating with customers, providing instructions to identify affected lots, discontinue use, and obtain replacement pods at no cost. Insulet states it has sufficient inventory to replace the affected pods and does not anticipate any disruption to product availability.
